Drug intelligence / Profile preview

Betamethasone dipropionate + methoxsalen + salicylic acid

Development stage: Unknown
Lead developer: Organon
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Topical

Overview

This combination involves **betamethasone dipropionate**, a corticosteroid used to reduce inflammation and itching; **methoxsalen**, a photosensitizer used in PUVA therapy for conditions like psoriasis; and **salicylic acid**, a keratolytic agent that helps remove dead skin cells. The combination would theoretically be used for treating severe skin conditions like psoriasis, combining anti-inflammatory, keratolytic, and photosensitizing effects.

Targets

GR (Glucocorticoid receptor)DNA

Beyond the preview

Go deeper on Betamethasone dipropionate + methoxsalen + salicylic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Betamethasone dipropionate + methoxsalen + salicylic acid.

Explore the full profile